Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Godavari Drugs Ltd (530317)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 530317 NSE: Pharmaceuticals & Drugs | Small Cap | Godavari Drugs Share Price
₹119.04 -1.57 (-1.30%)
As on 11-Sep'26 16:59
Godavari Drugs Ltd (530317)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 530317 NSE: Pharmaceuticals & Drugs | Small Cap | Godavari Drugs Share Price
₹119.04 -1.57 (-1.30%)
As on 11-Sep'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹130 Cr.
Current Price
₹119
52-Week Low / High
₹70 / 135
TTM EPS
-
TTM Sales
-
Book Value per Share
-
P/E Ratio
Industry PE
54.2
Price to Book (P/B)
Price to Sales (P/S)
EV/EBITDA
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
%
Return on Capital Employed (ROCE)
%
Return on Assets (ROA)
%
Operating Profit Margin
0%
Net Profit Margin
-%
Gross Profit Margin
0%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
-27.67%
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
40.23%
Pledged shares (%) of Promoter's holding (%)
0.21%
Reserves
-
Equity
₹10.9 Cr.
Face Value
₹10
All Time Low / High
₹1.00 / 155.00
Check Before You Invest
Quality
Not GoodValuation
OvervaluedCheck Valuation charts
Price Trend
Weak
Is Godavari Drugs Ltd a good quality company?
Godavari Drugs Ltd is a weak quality company, based on a inconsistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Godavari Drugs Ltd performance compare with that of its Peers?
Revenue growth of Godavari Drugs Ltd vs industry peers?
Godavari Drugs Ltd revenue CAGR is %, compared to the industry median CAGR of 0%, indicating stable growth and maintaining its market share.
Promoter shareholding and pledge status of Godavari Drugs Ltd?
Promoters hold 40.23% of the Godavari Drugs Ltd, with 0.21% of their stake pledged, indicating low pledge risk.
Stock return of Godavari Drugs Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 12.1% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Godavari Drugs Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good
Value Creation ⓘ
| Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 15.8% | 16.9% | 11% | 12.1% | 11.8% | 17.6% | 18.4% | 12.4% | 12.6% | 10.1% | - |
| Value Creation Index ⓘ | 0.1 | 0.2 | -0.2 | -0.1 | -0.2 | 0.3 | 0.3 | -0.1 | -0.1 | -0.3 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 71.1 | 75.6 | 64.5 | 83.5 | 95.7 | 123 | 161 | 160 | 157 | 113 | 110 |
| Sales YoY Gr. | - | 6.3% | -14.8% | 29.6% | 14.6% | 28.2% | 31.3% | -0.9% | -1.8% | -27.7% | - |
| Adj EPS ⓘ | 1.7 | 1.7 | 0.8 | 1.6 | 2.6 | 5.3 | 7.2 | 6.5 | 7.6 | 6.1 | 3.8 |
| YoY Gr. | - | 2.4% | -53.2% | 91.4% | 68.4% | 103.5% | 35.2% | -9.6% | 17.1% | -20.1% | - |
| BVPS (₹) ⓘ | 19.1 | 21.5 | 22.6 | 24.2 | 26.9 | 32.4 | 39.4 | 44.4 | 51.7 | 57.6 | 72.1 |
| Adj Net Profit ⓘ | 1.3 | 1.3 | 0.6 | 1.2 | 2 | 4 | 5.4 | 4.9 | 5.7 | 4.6 | 4 |
| Cash Flow from Ops. ⓘ | -4.5 | 5.2 | 3.8 | 3.7 | 6.2 | 1.3 | 11.2 | 13.2 | 18.4 | 11.2 | - |
| Debt/CF from Ops. ⓘ | -3.4 | 3.1 | 5 | 5.9 | 4.4 | 22.9 | 2.1 | 4.3 | 3.1 | 5.8 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 5.3% | 3.4% | -11.1% | -27.7% | ||||
| Adj EPS ⓘ | 15.3% | 18.4% | -5.4% | -20.1% | ||||
| BVPSⓘ | 13% | 16.4% | 13.5% | 11.3% | ||||
| Share Price | 12.3% | 10% | 5.5% | 36.4% | ||||
Key Financial Parameters ⓘ
| Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 9.3 | 8.5 | 3.7 | 6.6 | 10.2 | 17.9 | 20 | 15.5 | 15.8 | 11.1 | 5.9 |
| Op. Profit Mgn % ⓘ | 6.4 | 7 | 6.3 | 6.6 | 6.3 | 8 | 7.2 | 7.4 | 8.6 | 10.7 | 9 |
| Net Profit Mgn % ⓘ | 1.8 | 1.7 | 1 | 1.4 | 2.1 | 3.3 | 3.4 | 3.1 | 3.7 | 4 | 3.8 |
| Debt to Equity ⓘ | 1.1 | 1 | 1.1 | 1.2 | 1.4 | 1.3 | 0.8 | 1.7 | 1.5 | 1.5 | - |
| Working Cap Days ⓘ | 154 | 180 | 249 | 221 | 219 | 188 | 157 | 179 | 200 | 266 | 150 |
| Cash Conv. Cycle ⓘ | 58 | 60 | 78 | 72 | 75 | 70 | 50 | 82 | 113 | 135 | 21 |
Valuation of Godavari Drugs - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 1.25 | 1.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.22 | 0.22 | 0.21 | 0.21 |
* Pledged shares as % of Promoter's holding (%)
Financials
No data found!
No data found!
No data found!
No data found!
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Godavari Drugs Ltd FAQs
The current trading price of Godavari Drugs on 11-Sep-2026 16:59 is ₹119.0.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 10-Sep-2026 the market cap of Godavari Drugs stood at ₹129.9 Cr
The latest P/E ratio of Godavari Drugs as of 10-Sep-2026 is 31.26.
The latest P/B ratio of Godavari Drugs as of 10-Sep-2026 is 1.65.
The 52-week high of Godavari Drugs is ₹135.2 and the 52-week low is ₹69.70.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Godavari Drugs is ₹110 ( Cr.) .
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Godavari Drugs Ltd is a below average quality company.
The key valuation ratios of Godavari Drugs Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Godavari Drugs Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
About Godavari Drugs Ltd
Godavari Drugs was incorporated as a private limited company on December 2, 1987 and subsequently converted into a public limited company on September 25, 1992. It was promoted by Ghanshyam Jaju, Mukund Kakani and PC Shrimal.
The company has set up a project to manufacture 180 TPA at Sulphamethoxazole (SMX) in 1988. The project is located at Maharashtra Industrial Development Corporation (MIDC), Nanded, a notified class ‘C’ backward district in Maharashtra. The project was fully commissioned on July 3, 1989.
The registered office of the company is located at Secunderabad in Andhra Pradesh and Mukund Kakani is its Managing Director.
Business area of the company
The company’s principal activity is to manufacture and sell bulk drugs. It undertakes contract manufacturing from various organizations. The products include Pyrazinamide and Ethambutol HCL.
You have 48 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
